Form 4: United Therapeutics EVP Sells Shares Under 10b5-1 Plan

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares of common stock on November 13, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President & General Counsel of United Therapeutics Corp (UTHR), reported transactions on November 13, 2025.
• Mahon exercised 11,000 stock options at an exercise price of $135.42 per share.
• Concurrently, Mahon sold 11,000 shares of common stock obtained from the option exercise.
• The sales were executed in multiple trades at weighted average prices ranging from $456.39 to $469.09 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 plan established on December 24, 2024.
• Following these transactions, Mahon directly beneficially owns 36,781 shares of United Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen negatively, it was executed under a pre-arranged 10b5-1 plan, which suggests a planned financial management activity rather than a reaction to negative company-specific news. The significant profit from option exercise is a positive for the individual, but the reduction in direct ownership is a slight negative from an investor's perspective.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to immediate company news.
• The exercise price of the options was significantly lower ($135.42) than the sale prices (ranging from $456.39 to $469.09), indicating a substantial gain for the insider.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction (exercise of options and sale of shares) by an executive at United Therapeutics. Such transactions are common across various industries, particularly when executives manage their equity compensation and diversification under pre-planned trading arrangements like Rule 10b5-1 plans. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by an executive slightly reduces insider ownership, which some investors might view as a minor negative, though it's a common practice under 10b5-1 plans.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, Paul A. Mahon, Executive Vice President, General Counsel, Equity Sales